Follow-up studies from the same laboratory used mice treated exogenously with CXCL9, which reduced the severity of liver fibrosis as assessed by Sirius red staining, hydroxyproline assay, and α-SMA expression63 (Table 1).In vivo CXCL9 treatment also inhibited angiogenesis as assessed by CD31 staining and ultrasound visualization of liver perfusion. The gene discussed is CXCL9; the disease is Hepatic fibrosis.